VistaGen Therapeutics, Inc

(NASDAQ:VTGN)

Latest On VistaGen Therapeutics, Inc (VTGN):

Date/Time Type Description Signal Details
2023-03-22 19:01 ESTNewsVistagen up 17% after Phase 3 data for anxiety candidateN/A
2023-03-03 13:33 ESTNewsVistaGen readies 12M-share secondary offeringN/A
2023-03-01 18:06 ESTNewsVistagen secures new U.S. patent for PH80 nasal spray for migraineN/A
2023-02-10 19:53 ESTNewsVistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call TranscriptN/A
2023-02-08 14:13 ESTNewsVistaGen slips as mid-stage study for anxiety therapy remains on holdN/A
2023-02-08 00:59 ESTNewsVistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.18M misses by $0.13MN/A
2022-12-21 12:33 ESTNewsVistaGen acquiring Pherin Pharma acquisition to bolster neuropsychiatric portfolioN/A
2022-12-06 09:32 ESTNewsVistagen surges 30% on FDA fast track status for nasal spray for depressionN/A
2022-12-01 01:38 ESTNewsVistagen stock rises ~10% on FDA nod to proceed with trial for depression nasal sprayN/A
2022-11-11 01:04 ESTNewsVistaGen Therapeutics GAAP EPS of -$0.08N/A
2022-11-11 01:03 ESTNewsVistaGen Therapeutics, Inc. (VTGN) Q2 2023 Earnings Call TranscriptN/A
2022-11-10 07:32 ESTNewsVistaGen Therapeutics Q2 2023 Earnings PreviewN/A
2022-09-08 19:24 ESTNewsVistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysisN/A
2022-08-13 02:54 ESTNewsVistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line missN/A
2022-08-13 02:54 ESTNewsVistaGen Therapeutics, Inc.'s (VTGN) CEO Shawn Singh on Q1 2023 Results -Earnings Call TranscriptN/A
2022-08-11 17:37 ESTNewsVistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M beats by $0.07MN/A
2022-08-11 01:22 ESTNewsVistaGen Therapeutics FQ1 2023 Earnings PreviewN/A
2022-07-25 19:58 ESTNewsVistaGen downgraded to neutral at Baird on pivotal trial failureN/A
2022-07-23 00:11 ESTNewsVistaGen drops 80% as late-stage study for anxiety therapy failsN/A
2022-06-24 15:56 ESTNewsVistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call TranscriptN/A
2022-06-24 15:55 ESTNewsVistaGen stock down 7% on disappointing FY resultN/A
2022-06-23 22:04 ESTNewsVistaGen Therapeutics GAAP EPS of -$0.25 misses by $0.03, revenue of $1.11M misses by $0.21MN/A
2022-05-05 12:48 ESTNewsVistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxietyN/A
2022-04-12 18:53 ESTNewsVistaGen, AffaMed plan to start global study of nasal spray PH94B for anxiety in H2N/A
2022-02-11 11:15 ESTNewsVistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call TranscriptN/A
2022-02-10 17:42 ESTNewsVistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11MN/A
2022-02-09 20:44 ESTNewsVistaGen Therapeutics Q3 2022 Earnings PreviewN/A
2021-11-11 15:24 ESTNewsVistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call TranscriptN/A
2021-11-10 18:14 ESTNewsVistaGen Therapeutics EPS misses by $0.01, beats on revenueN/A
2021-11-09 19:29 ESTNewsVistaGen Therapeutics Q2 2022 Earnings PreviewN/A
2021-10-15 03:30 ESTNewsVistaGen Therapeutics expands clinical development of PH94B in Adjustment Disorder with AnxietyN/A
2021-08-13 02:49 ESTNewsVistaGen Therapeutics EPS beats by $0.01, misses on revenueN/A
2021-08-13 02:48 ESTNewsVistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call TranscriptN/A
2021-07-23 09:16 ESTNewsVistaGen Therapeutics adds Maggie FitzPatrick to its board of directorsN/A
2021-07-22 08:46 ESTNewsVistaGen initiates late-stage trial of PH94B in social anxiety disorderN/A
2021-07-22 08:23 ESTNewsVistaGen Therapeutics added to Russell 2000 IndexN/A
2021-07-22 08:04 ESTNewsVistaGen Therapeutics EPS misses by $0.27, beats on revenueN/A
2021-07-22 08:04 ESTNewsVistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call TranscriptN/A
2021-07-22 08:01 ESTNewsVistaGen Therapeutics (VTGN) Investor Presentation - SlideshowN/A
2021-07-22 07:51 ESTNewsVistaGen appoints Mary Rotunno to board of directorsN/A
2021-05-05 05:28 ESTNewsVistaGen names new chief commercial officerN/A
2021-04-26 09:15 ESTNewsVistaGen Therapeutics: SAD And MDD Antidepressants May Finally Be Ready To DeliverN/A
2021-04-25 13:31 ESTNewsVistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To BeginN/A
2021-03-17 11:31 ESTNewsVistaGen Therapeutics files for $250M mixed shelfN/A
2021-02-19 00:55 ESTAnalyst RatingThe Analyst Target Price has increased from $5.5 to $5.67.Buy
2021-02-19 00:15 ESTNewsVistaGen initiated with Buy at Jefferies on 'upside potential' for anxiety drugN/A
2021-02-12 12:35 ESTEarnings EstimateAn EPS average of -$0.05 is estimated for the quarter ending on June 30, 2021.Buy
2021-02-12 08:46 ESTNewsVistaGen Therapeutics EPS misses by $0.02, beats on revenueN/A
2021-02-12 04:51 ESTFinancialsCompany financials have been released.Neutral
2021-01-24 02:03 ESTNewsVistaGen: Patience Could Lead To Significant UpsideN/A

About VistaGen Therapeutics, Inc (VTGN):

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

VTGN Quotes by TradingView

See Advanced Chart

General

  • Name VistaGen Therapeutics, Inc
  • Symbol VTGN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 11
  • Last Split Factor1:20
  • Last Split Date2014-08-14
  • Fiscal Year EndMarch
  • IPO Date2016-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.vistagen.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 223.83
  • Price/Book (Most Recent Quarter) 3.55
  • Enterprise Value Revenue 359.11
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.23
  • Next Year EPS Estimate -$0.25
  • Next Quarter EPS Estimate -$0.04
  • Operating Margin -2313%
  • Return on Assets -16%
  • Return on Equity -30%
  • Revenue 647600
  • Earnings Per Share -$0.83
  • Revenue Per Share $0.01
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 324.19 million
  • EBITDA -26467900
  • Analyst Target Price $5.67
  • Book Value Per Share $0.68
View More

Share Statistics

  • Shares Outstanding 143.76 million
  • Shares Float 109.05 million
  • % Held by Insiders 448%
  • % Held by Institutions 7.53%
  • Shares Short 8.51 million
  • Shares Short Prior Month 5.25 million
  • Short Ratio 1.54
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 0.88
  • 52 Week High $3.18
  • 52 Week Low $0.35
  • 50 Day Moving Average 2.22
  • 200 Day Moving Average 1.33
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

VistaGen Therapeutics, Inc (VTGN) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

VistaGen Therapeutics, Inc (VTGN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$313600-$0.07-$0.05-31.33%
2020-09-302020-11-12$334000-$0.05-$0.02-114.59%
2020-06-302020-08-13$N/A-$0.07-$0.1030%
2020-03-312020-06-29$N/A-$0.07-$0.0812.5%
2019-12-312020-02-13$N/A-$0.15-$0.07-114.29%
2019-09-302019-11-07$N/A-$0.13-$0.143.7%
2019-06-302019-08-13$N/A-$0.15-$0.11-36.36%
2019-03-312019-06-25$N/A-$0.17-$0.2119.05%
2018-12-312019-02-12$N/A-$0.24-$0.22-11.63%
2018-09-302018-10-29$N/A-$0.30-$0.17-76.47%
2018-06-302018-08-14$N/A-$0.20-$0.14-42.86%
2018-03-312018-06-26$N/A-$0.09-$0.2867.39%
2017-12-312018-02-12$N/A-$0.23-$0.6765.67%
2017-09-302017-11-09$N/A-$0.53-$0.47-13%
2017-06-302017-08-14$N/A-$0.28-$0.4131.71%
2017-03-312017-06-29$N/A-$0.32-$0.5238.46%
2016-12-312017-02-13$1.25 million-$0.34-$0.378.11%
2016-09-302016-11-14$N/A-$0.42-$0.38-10.53%
2016-06-302016-08-12$N/A-$0.51-$0.568.93%
2016-03-312016-06-24$N/A-$4.44-$1.80-146.67%
2015-12-312016-02-16$N/A-$1.95-$6.4369.67%
2015-09-302015-11-16$N/A-$5.26
2015-06-302015-08-14$N/A-$19.23
2015-03-312015-06-29$N/A-$5.49-$0.84-553.57%
2014-12-312015-02-17$N/A-$1.08
2014-09-302014-11-19$N/A-$1.90
2014-06-302014-08-12$N/A-$3.70
2014-03-312014-03-31$N/A-$1.57
2013-12-312013-12-31$N/A-$0.44
2013-09-302013-09-30$N/A-$1.35
2013-06-302013-06-30$N/A-$0.44
2013-03-312013-03-31$200000-$3.73
2012-12-312012-12-31$N/A-$13.62
2012-09-302012-09-30$-200000-$2.32
2012-06-302012-06-30$200000-$2.17
2012-03-312012-03-31$469000-$4.13
2011-12-312011-12-31$2000-$5.61
2011-09-302011-09-30$316000-$2.96
2011-06-302011-06-30$555000-$4.48

VistaGen Therapeutics, Inc (VTGN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 3.5 million 2.36 million 1.73 million N/A 2.88 million
Income Before Tax -5.3 million -3.3 million -3.12 million N/A -5.96 million
Selling General Administrative 2.12 million 1.24 million 1.39 million N/A 3.08 million
Gross Profit 313600 N/A N/A N/A N/A
Ebit -5.3 million -3.27 million -3.1 million N/A -5.96 million
Operating Income -5.3 million -3.26 million -3.12 million N/A -5.96 million
Income Tax Expense N/A N/A 2400 N/A 200
Total Revenue 313600 334000 N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A 600 N/A 1500
Net Income From Continuing Operations -5.3 million -3.3 million -3.13 million N/A -5.96 million
Net Income Applicable to Common Shares -5.65 million N/A -3.46 million -3.59 million -6.28 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -98800 N/A N/A N/A N/A
Change to Liabilities N/A -434400 N/A -1.1 million 884300
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A 173700 N/A -89500 -87900
Total Cash Flow from Financial Activities 12.95 million 3 million N/A 1.27 million -87900
Change to Operating Activities N/A 54500 N/A 300700 -131100
Change in Cash 13.85 million 190800 N/A -3.01 million -4.22 million
Total Cash from Operating Activities 1 million -2.81 million N/A -4.28 million -4.14 million
Depreciation 25500 25400 N/A 25500 25900
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A -29400 N/A 300000 N/A
Change to Net Income N/A 674600 N/A 2.46 million 420000
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 15.46 million 16.05 million 11.78 million N/A 6.74 million
Total Stockholder Equity 93.81 million 4.22 million -5.61 million N/A -6.1 million
Other Current Liabilities 1.6 million 1.24 million N/A N/A N/A
Total Assets 109.27 million 20.27 million 6.17 million N/A 5.33 million
Common Stock 138800 74100 55900 49300 44200
Other Current Assets 664400 3900 1600 N/A 199700
Retained Earnings -213.63 million -208.33 million -205.03 million -201.91 million -198.64 million
Other Liabilities N/A 3.42 million N/A N/A N/A
Other Assets N/A 638000 311700 402900 47800
Cash 104.33 million 15.4 million 1.55 million N/A 1.06 million
Total Current Liabilities 2.98 million 3.3 million 2.67 million N/A 2.94 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 382200 3.66 million 3.68 million 3.79 million 3.9 million
Total Current Assets 105 million 15.97 million 2.18 million N/A 1.38 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 93.8 million 4.22 million -5.62 million -5.73 million -6.1 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A 87300 124700 N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.28 million 1.18 million 1.31 million N/A 1.61 million

VistaGen Therapeutics, Inc (VTGN) Chart:

VistaGen Therapeutics, Inc (VTGN) News:

Below you will find a list of latest news for VistaGen Therapeutics, Inc (VTGN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

VistaGen Therapeutics, Inc (VTGN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1713.6CALL0 01328.07TRUE00
2024-05-1722.95CALL0 91711.09TRUE00
2024-05-1732.2CALL0 39256.16TRUE00
2024-05-1740.65CALL1 58105.77TRUE0.650
2024-05-1750.1CALL8 166378.35FALSE0.051
2024-05-1760.05CALL0 21810FALSE00
2024-05-1770.24CALL0 810FALSE00
2024-05-1780.05CALL0 620FALSE00
2024-05-1790.12CALL0 1150FALSE00
2024-05-17100.05CALL0 1040FALSE00
2024-05-17110.15CALL0 110FALSE00
2024-05-17120.05CALL0 960FALSE00
2024-05-17130.25CALL0 20FALSE00
2024-05-1710PUT0 00FALSE00
2024-05-1720PUT0 00FALSE00
2024-05-1730.9PUT0 60FALSE00
2024-05-1740.06PUT71 100572.02FALSE0.010.2
2024-05-1750.37PUT0 15372.06TRUE00
2024-05-1761.3PUT0 15156.16TRUE00
2024-05-1770PUT0 0323.86TRUE00
2024-05-1780PUT0 0176.21TRUE00
2024-05-1790PUT0 00TRUE00
2024-05-17100PUT0 0288.25TRUE00
2024-05-17110PUT0 0365.42TRUE00
2024-05-17120PUT0 0295.38TRUE00
2024-05-17130PUT0 0382.59TRUE00
2024-06-2110CALL0 0260.49TRUE00
2024-06-2120CALL0 0242.66TRUE00
2024-06-2130CALL0 0252.23TRUE00
2024-06-2140.85CALL17 1089.49TRUE0.850
2024-06-2150.25CALL0 2284.77FALSE00
2024-06-2160.2CALL0 740FALSE00
2024-06-2170.1CALL0 10FALSE00
2024-06-2180.1CALL0 40FALSE00
2024-06-2190CALL0 00FALSE00
2024-06-2110PUT0 00FALSE00
2024-06-2120PUT0 00FALSE00
2024-06-2130PUT0 00FALSE00
2024-06-2140PUT0 076.44FALSE00
2024-06-2150PUT0 0105.18TRUE00
2024-06-2160PUT0 0126.18TRUE00
2024-06-2170PUT0 0132.58TRUE00
2024-06-2180PUT0 0237.2TRUE00
2024-06-2190PUT0 0257.66TRUE00
2024-08-1610CALL0 0412.62TRUE00
2024-08-1624.2CALL0 3154.81TRUE00
2024-08-1631.96CALL0 484.67TRUE00
2024-08-1641.01CALL0 1885.61TRUE00
2024-08-1650.65CALL0 63132.42FALSE00
2024-08-1660.35CALL0 1144107.86FALSE00
2024-08-1670.4CALL0 1587.37FALSE00
2024-08-1680.25CALL0 28620FALSE00
2024-08-1690.61CALL0 50FALSE00
2024-08-16100.15CALL0 1840FALSE00
2024-08-1610PUT0 00FALSE00
2024-08-1620PUT0 00FALSE00
2024-08-1630PUT0 0128.25FALSE00
2024-08-1640.53PUT0 51186.55FALSE00
2024-08-1651PUT0 54134.34TRUE00
2024-08-1660PUT0 0131.76TRUE00
2024-08-1670PUT0 0103.63TRUE00
2024-08-1680PUT0 099.43TRUE00
2024-08-1690PUT0 0139.95TRUE00
2024-08-16100PUT0 0131.5TRUE00
2024-11-1510CALL0 0190.92TRUE00
2024-11-1520CALL0 062.98TRUE00
2024-11-1530CALL0 0115.46TRUE00
2024-11-1540CALL0 0117.98TRUE00
2024-11-1550.4CALL0 083.38FALSE00
2024-11-1560CALL0 098.45FALSE00
2024-11-1570.65CALL0 192.41FALSE00
2024-11-1580CALL0 096.04FALSE00
2024-11-1590.15CALL0 50FALSE00
2024-11-1510PUT0 00FALSE00
2024-11-1520.15PUT0 10FALSE00
2024-11-1530PUT0 00FALSE00
2024-11-1540.8PUT0 566109.24FALSE00
2024-11-1551.3PUT0 1194.98TRUE00
2024-11-1560PUT0 095.77TRUE00
2024-11-1570PUT0 0106.42TRUE00
2024-11-1580PUT0 0101.28TRUE00
2024-11-1590PUT0 0103.1TRUE00
2025-01-1710CALL0 0180.41TRUE00
2025-01-1722.89CALL0 36122.88TRUE00
2025-01-1732.27CALL0 1877.6TRUE00
2025-01-1741.55CALL6 5187.59TRUE-0.1-0.06
2025-01-1751.5CALL0 9590.23FALSE00
2025-01-1760CALL0 083.08FALSE00
2025-01-1770.75CALL0 2110FALSE00
2025-01-1780CALL0 084.61FALSE00
2025-01-17100.5CALL0 51992.55FALSE00
2025-01-17120.25CALL0 3330FALSE00
2025-01-1710PUT0 00FALSE00
2025-01-1720.6PUT0 1172.87FALSE00
2025-01-1730.5PUT0 34135.49FALSE00
2025-01-1741PUT0 3106.23FALSE00
2025-01-1751.78PUT0 72108.55TRUE00
2025-01-1760PUT0 0106.99TRUE00
2025-01-1770PUT0 0106.64TRUE00
2025-01-1780PUT0 0101.46TRUE00
2025-01-17100PUT0 0101.04TRUE00
2025-01-17120PUT0 0137.88TRUE00
2026-01-1623CALL5 583.7TRUE0.30.11
2026-01-1633.1CALL0 36189.63TRUE00
2026-01-1642.85CALL0 15160.01TRUE00
2026-01-1652.4CALL0 123101.73FALSE00
2026-01-1672.25CALL0 25112.74FALSE00
2026-01-16101.45CALL30 659102.79FALSE00
2026-01-16121.8CALL0 83172.54FALSE00
2026-01-1620PUT0 0142.73FALSE00
2026-01-1630.91PUT0 55158.37FALSE00
2026-01-1642.06PUT0 1130.27FALSE00
2026-01-1652.45PUT0 1144.18TRUE00
2026-01-1670PUT0 0101.67TRUE00
2026-01-16100PUT0 0114.03TRUE00
2026-01-16120PUT0 0116.22TRUE00

Latest VTGN Trades:

Date Shares Price
Jun 13, 2022 7:53 PM EST200$0.9301
Jun 13, 2022 7:54 PM EST100$0.9373
Jun 13, 2022 7:58 PM EST57$0.9504
Jun 13, 2022 7:58 PM EST200$0.9401
Jun 13, 2022 7:59 PM EST100$0.94

VistaGen Therapeutics, Inc (VTGN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001767/0001415889-20-001767-index.htm
2019-10-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1411685/000000000019014276/0000000000-19-014276-index.htm
2020-04-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1411685/000000000020002992/0000000000-20-002992-index.htm
2020-05-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1411685/000000000020004027/0000000000-20-004027-index.htm
2020-09-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000101905620000505/0001019056-20-000505-index.htm
2020-01-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000110465920007804/0001104659-20-007804-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000117891319000442/0001178913-19-000442-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000117891320000343/0001178913-20-000343-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000121390019001922/0001213900-19-001922-index.htm
2018-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588918001318/0001415889-18-001318-index.htm
2018-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588918001319/0001415889-18-001319-index.htm
2018-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588918001320/0001415889-18-001320-index.htm
2018-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588918001321/0001415889-18-001321-index.htm
2018-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588918001322/0001415889-18-001322-index.htm
2018-09-21DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588918001409/0001415889-18-001409-index.htm
2019-01-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000050/0001415889-19-000050-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000051/0001415889-19-000051-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000052/0001415889-19-000052-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000107/0001415889-19-000107-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000179/0001415889-19-000179-index.htm
2019-03-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000287/0001415889-19-000287-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000320/0001415889-19-000320-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000322/0001415889-19-000322-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000581/0001415889-19-000581-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000583/0001415889-19-000583-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000585/0001415889-19-000585-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000587/0001415889-19-000587-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000589/0001415889-19-000589-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000591/0001415889-19-000591-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000593/0001415889-19-000593-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000595/0001415889-19-000595-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919000597/0001415889-19-000597-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001207/0001415889-19-001207-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001208/0001415889-19-001208-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001209/0001415889-19-001209-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001210/0001415889-19-001210-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001211/0001415889-19-001211-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001212/0001415889-19-001212-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001213/0001415889-19-001213-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001214/0001415889-19-001214-index.htm
2019-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001215/0001415889-19-001215-index.htm
2019-11-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001357/0001415889-19-001357-index.htm
2019-12-12DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588919001479/0001415889-19-001479-index.htm
2020-01-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920000199/0001415889-20-000199-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001060/0001415889-20-001060-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001061/0001415889-20-001061-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001062/0001415889-20-001062-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001063/0001415889-20-001063-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001064/0001415889-20-001064-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001065/0001415889-20-001065-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001066/0001415889-20-001066-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001067/0001415889-20-001067-index.htm
2020-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001068/0001415889-20-001068-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001764/0001415889-20-001764-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001765/0001415889-20-001765-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001766/0001415889-20-001766-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920001767/0001415889-20-001767-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411685/000141588920002181/0001415889-20-002181-index.htm
2019-01-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411685/000153561019000010/0001535610-19-000010-index.htm
2018-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418010158/0001654954-18-010158-index.htm
2018-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418010271/0001654954-18-010271-index.htm
2018-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418010862/0001654954-18-010862-index.htm
2018-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418011619/0001654954-18-011619-index.htm
2018-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495418011665/0001654954-18-011665-index.htm
2018-10-3010-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495418011715/0001654954-18-011715-index.htm
2018-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418011717/0001654954-18-011717-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418012521/0001654954-18-012521-index.htm
2018-12-138-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495418013924/0001654954-18-013924-index.htm
2019-01-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419000399/0001654954-19-000399-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419000496/0001654954-19-000496-index.htm
2019-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419000925/0001654954-19-000925-index.htm
2019-02-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495419001372/0001654954-19-001372-index.htm
2019-02-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411685/000165495419001943/0001654954-19-001943-index.htm
2019-02-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411685/000165495419002032/0001654954-19-002032-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419002248/0001654954-19-002248-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419002743/0001654954-19-002743-index.htm
2019-04-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419004073/0001654954-19-004073-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419005208/0001654954-19-005208-index.htm
2019-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419007549/0001654954-19-007549-index.htm
2019-06-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1411685/000165495419007632/0001654954-19-007632-index.htm
2019-07-12PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1411685/000165495419008227/0001654954-19-008227-index.htm
2019-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419008430/0001654954-19-008430-index.htm
2019-07-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1411685/000165495419008434/0001654954-19-008434-index.htm
2019-07-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1411685/000165495419008511/0001654954-19-008511-index.htm
2019-07-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1411685/000165495419008514/0001654954-19-008514-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495419009386/0001654954-19-009386-index.htm
2019-08-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419009727/0001654954-19-009727-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419009965/0001654954-19-009965-index.htm
2019-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419010432/0001654954-19-010432-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419011097/0001654954-19-011097-index.htm
2019-09-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411685/000165495419011259/0001654954-19-011259-index.htm
2019-10-01S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1411685/000165495419011260/0001654954-19-011260-index.htm
2019-10-01S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1411685/000165495419011261/0001654954-19-011261-index.htm
2019-10-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1411685/000165495419011429/0001654954-19-011429-index.htm
2019-10-04S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411685/000165495419011430/0001654954-19-011430-index.htm
2019-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419011552/0001654954-19-011552-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419012073/0001654954-19-012073-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495419012431/0001654954-19-012431-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419012501/0001654954-19-012501-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419012881/0001654954-19-012881-index.htm
2019-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419013881/0001654954-19-013881-index.htm
2019-12-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495419014268/0001654954-19-014268-index.htm
2020-01-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420000737/0001654954-20-000737-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420000744/0001654954-20-000744-index.htm
2020-01-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420001014/0001654954-20-001014-index.htm
2020-02-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420001517/0001654954-20-001517-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420001518/0001654954-20-001518-index.htm
2020-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420001787/0001654954-20-001787-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420003246/0001654954-20-003246-index.htm
2020-03-31S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411685/000165495420003617/0001654954-20-003617-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420003788/0001654954-20-003788-index.htm
2020-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1411685/000165495420003958/0001654954-20-003958-index.htm
2020-04-10S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411685/000165495420003959/0001654954-20-003959-index.htm
2020-04-15424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420004113/0001654954-20-004113-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420004484/0001654954-20-004484-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420004559/0001654954-20-004559-index.htm
2020-05-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411685/000165495420004837/0001654954-20-004837-index.htm
2020-05-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1411685/000165495420005108/0001654954-20-005108-index.htm
2020-05-11S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411685/000165495420005109/0001654954-20-005109-index.htm
2020-05-15424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420005649/0001654954-20-005649-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420005728/0001654954-20-005728-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420006204/0001654954-20-006204-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420007024/0001654954-20-007024-index.htm
2020-06-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1411685/000165495420007107/0001654954-20-007107-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420007163/0001654954-20-007163-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420007962/0001654954-20-007962-index.htm
2020-07-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1411685/000165495420008042/0001654954-20-008042-index.htm
2020-07-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1411685/000165495420008044/0001654954-20-008044-index.htm
2020-07-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420008269/0001654954-20-008269-index.htm
2020-08-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420008335/0001654954-20-008335-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420008543/0001654954-20-008543-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411685/000165495420009069/0001654954-20-009069-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420009204/0001654954-20-009204-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420010220/0001654954-20-010220-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411685/000165495420011086/0001654954-20-011086-index.htm
2019-10-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1411685/999999999519002263/9999999995-19-002263-index.htm
2020-04-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1411685/999999999520000750/9999999995-20-000750-index.htm
2020-05-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1411685/999999999520001147/9999999995-20-001147-index.htm
2018-10-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1411685/999999999718008248/9999999997-18-008248-index.htm
2018-12-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1411685/999999999718009564/9999999997-18-009564-index.htm

VistaGen Therapeutics, Inc (VTGN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of VistaGen Therapeutics, Inc (VTGN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 448%
Institutional Ownership: 753%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-13JON S SAXEDirectorBuy12,080.001.2615,201.4712,080.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000322/0001415889-19-000322-index.htm
2019-11-20H. RALPH SNODGRASSPRES./CHIEF SCIENTIFIC OFFICERBuy15,000.000.345,100.0015,000.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919001357/0001415889-19-001357-index.htm
2019-03-14JON S SAXEDirectorBuy7,920.001.2710,086.1220,000.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000322/0001415889-19-000322-index.htm
2019-01-14Shawn SinghCHIEF EXECUTIVE OFFICERBuy21,250.001.5031,875.0021,250.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm
2019-01-14Shawn SinghCHIEF EXECUTIVE OFFICERBuy1,125.001.501,687.5022,375.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm
2019-01-29JON S SAXEDirectorBuy375.001.50562.502,251.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000107/0001415889-19-000107-index.htm
2019-01-14Shawn SinghCHIEF EXECUTIVE OFFICERBuy3,000.001.504,500.0025,375.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000055/0001415889-19-000055-index.htm
2020-06-30Shawn SinghCHIEF EXECUTIVE OFFICERBuy5,000.000.452,240.0030,375.00https://www.sec.gov/Archives/edgar/data/1411685/000141588920001764/0001415889-20-001764-index.htm
2019-01-29JON S SAXEDirectorBuy1,000.001.501,500.003,251.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000107/0001415889-19-000107-index.htm
2020-06-30JERROLD DUANE DOTSONVP, CFO AND SECRETARYBuy5,000.000.452,240.005,000.00https://www.sec.gov/Archives/edgar/data/1411685/000141588920001765/0001415889-20-001765-index.htm
2020-06-30Mark Alan SmithCHIEF MEDICAL OFFICERBuy5,000.000.452,240.005,000.00https://www.sec.gov/Archives/edgar/data/1411685/000141588920001766/0001415889-20-001766-index.htm
2020-08-21JON S SAXEDirectorBuy30,000.000.6920,700.0050,000.00https://www.sec.gov/Archives/edgar/data/1411685/000141588920002181/0001415889-20-002181-index.htm
2019-03-13H. RALPH SNODGRASSPRES./CHIEF SCIENTIFIC OFFICERBuy2,500.001.503,750.0062,724.00https://www.sec.gov/Archives/edgar/data/1411685/000141588919000320/0001415889-19-000320-index.htm
2020-06-30H. RALPH SNODGRASSPRES./CHIEF SCIENTIFIC OFFICERBuy5,000.000.452,240.0067,724.00https://www.sec.gov/Archives/edgar/data/1411685/000141588920001767/0001415889-20-001767-index.htm